Register
Febuxostat and allopurinol similar in terms of cardiovascular outcomes |
Journal Updates
eMediNexus Coverage from: 
Febuxostat and allopurinol similar in terms of cardiovascular outcomes
eMediNexus,  13 March 2018
remove_red_eye 881 Views
#Cardiology #Internal Medicine #Pathology and Lab Medicine #Pharmacist #Rheumatology

1 Read Comments                

Febuxostat was similar to allopurinol with respect to rates of adverse cardiovascular events in patients with gout and major cardiovascular coexisting conditions, according to the CARES trial published March 12, 2018 in the New England Journal of Medicine. However, all-cause mortality and cardiovascular mortality were higher with febuxostat.

To continue reading this article
Or

Continue reading your article with a Emedinexus account..
Free Membership!